文献速递前列腺癌

THBS1与CTSD联检提升前列腺癌诊断并减少不必要穿刺

Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.
PubMed 文献 · BJU Int · 2018-10-11

该回顾性单中心研究纳入474例PSA 2.0-10 ng/mL、直肠指检阴性且前列腺体积≥35 mL的男性,在穿刺前检测血清THBS1、CTSD糖蛋白并联合%fPSA建立预测模型。验证集中模型诊断任何前列腺癌的AUC为0.86,显著优于%fPSA的0.64,90%灵敏度下特异度分别为62%和23%。

要点

  • THBS1、CTSD联合%fPSA可提升前列腺癌诊断准确性。
  • 90%灵敏度下模型特异度62%,高于%fPSA的23%。
  • 该模型有望减少因%fPSA特异度低导致的不必要穿刺。

核心结论

  • 联合THBS1、CTSD与%fPSA的模型可改善前列腺癌诊断,并可能减少不必要的前列腺穿刺。

研究设计与样本

  • 回顾性单中心研究,2011至2016年纳入474例拟行前列腺穿刺的男性,血清PSA 2.0-10 ng/mL、直肠指检阴性且前列腺体积≥35 mL。

主要发现

  • 验证集中联合模型区分穿刺阳性与阴性的AUC为0.86(P < 0.001,95%CI 0.82-0.91),%fPSA单独为0.64(P < 0.001,95%CI 0.57-0.71)。
  • 诊断任何前列腺癌在90%灵敏度下,联合模型特异度为62%,%fPSA为23%。
  • 诊断高级别前列腺癌(前列腺切除标本Gleason评分≥7)在90%灵敏度下,联合模型特异度为48%,AUC为0.83(P < 0.001,95%CI 0.77-0.88)。

关键数值与推荐

  • 联合模型诊断任何前列腺癌的AUC为0.86(95%CI 0.82-0.91)。
  • 联合模型诊断高级别前列腺癌的AUC为0.83(95%CI 0.77-0.88)。
  • 90%灵敏度下联合模型对任何前列腺癌的特异度为62%,对高级别前列腺癌为48%。

临床怎么用

  • 对PSA 2.0-10 ng/mL、直肠指检阴性且前列腺体积≥35 mL的男性,可考虑检测血清THBS1与CTSD并联合%fPSA评估穿刺必要性。

局限性

  • 研究为回顾性设计且为单中心队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate and further validate if two novel cancer-related glycoproteins, discovered by a genetic-guided proteomics approach, can distinguish benign disease from prostate cancer (PCa) in men with enlarged prostates. PATIENTS AND METHODS: A retrospective study was performed that included men with a total prostate-specific antigen (PSA) concentration of 2.0-10 ng/mL, negative digital rectal examination and enlarged prostate (volume ≥35 mL). Serum samples were collected between 2011 and 2016 at a single centre from 474 men before they underwent prostate biopsy. Serum concentrations of thrombospondin 1 (THBS1) and cathepsin D (CTSD) glycoproteins were combined with the percentage of free PSA to total PSA ratio (%fPSA) to predict any or significant cancer at biopsy. RESULTS: The multivariable logistic regression model including THBS1, CTSD and %fPSA discriminated among biopsy-positive and biopsy-negative patients in the validation set with an area under the curve (AUC) of 0.86 (P < 0.001, 95% confidence interval (CI) 0.82-0.91), while %fPSA alone showed an AUC of 0.64 (P < 0.001, 95% CI 0.57-0.71). At 90% sensitivity for PCa, the specificity of the model was 62%, while %fPSA had a specificity of 23%. For high grade (Gleason score ≥ 7 in prostatectomy specimen) PCa, the specificity was 48% at 90% sensitivity, with an AUC of 0.83, (P < 0.001, 95% CI 0.77 to 0.88). Limitations of the study include the retrospective set-up and single-centre cohort. CONCLUSIONS: A model combining two cancer-related glycoproteins (THBS1 and CTSD) and %fPSA can improve PCa diagnosis and may reduce the number of unnecessary prostate biopsies because of its improved specificity for PCa when compared to %fPSA alone.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Steuber T, Tennstedt P, Macagno A, et al. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies. BJU Int. 2018. PMID: 30216634. doi:10.1111/bju.14540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。